Key result
Mexiletine infusion challenge test shortens QTc and restores 1:1 AV conduction in neonatal LQT3.
Why the study?
Early detection of genotype in neonatal long QT syndrome is important for applying genotype-based treatment.
Does a mexiletine infusion challenge test improve QTc and AV conduction in a neonate with LQTS type 3?
Case Report (n=1)
Does a mexiletine infusion challenge test improve QTc and AV conduction in a neonate with LQTS type 3?
A mexiletine infusion challenge test can be useful for early genotype detection and predicting drug efficacy in neonatal LQTS type 3.
May aid early management in neonatal LQTS3; leaves open need for prospective validation before wider adoption.
For applying a genotype-based treatment in neonatal long QT syndrome (LQTS), early detection of the genotype becomes an important issue. We report a case of a neonate with LQTS type 3 that presented with 2:1 atrioventricular block and underwent a mexiletine infusion challenge test, and achieved shortening of the QTc and 1:1 atrioventricular conduction. The mexiletine infusion challenge test was helpful to make an early detection of the genotype of the LQTS and predicted the drug efficacy in a neonatal patient.
No takes yet. Share an insight, caveat, or question.
Okuwaki et al. (2019) conducted a case report in Neonatal long QT syndrome (LQTS) type 3 with 2:1 atrioventricular block (n=1). Mexiletine infusion challenge test was evaluated on Shortening of the QTc and 1:1 atrioventricular conduction. Mexiletine infusion challenge test achieved shortening of the QTc and 1:1 atrioventricular conduction in a neonate with long QT syndrome type 3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: